Partnership to explore supply chain orchestration in CGT manufacturing

A new industry partnership aims to achieve supply chain orchestration within closed system manufacturing for the cell and gene therapy sector.

The non-exclusive partnership brings together the respective expertise of TrakCel, a Welsh software developer for cell and gene therapy (CGT) supply chain tracking orchestration, and London-based innovator in cell and gene therapy manufacturing, Ori Biotech.

The Ori platform enables therapy developers and contract manufacturers to achieve automated CGT manufacturing in a closed platform.

The collaboration will enable users of the Ori Biotech manufacturing platform to benefit from live supply chain visibility through TrakCel software and TrakCel customers to have greater visibility into the manufacturing process via data services within the Ori platform.

Resulting from the agreement, TrakCel and Ori will develop suitable points of integration for a shared data platform to be available to partners.

“TrakCel has developed an extensive partnership network with contract manufacturers and companies across the cell and gene therapy sector. This enables therapeutic developers to be supported by more standardized and integrated solutions,” said Fiona Withey, co-founder and CEO of TrakCel.

“Closed system manufacturing is becoming progressively more important for the ongoing future of the cell and gene therapy sector, and we look forward to working with Ori to offer more integrated solutions to the wider industry.”

Farlan Veraitch, co-founder and CSO of Ori Biotech, added: “The integration of TrakCel’s advanced therapy supply chain tracking software with the Ori full-stack platform is another step forward enabling our customers to have full visibility throughout the supply chain.”

Help us maintain our standards of journalism

Readers enjoy our news site but keeping our news up to date and authoritative, without charging readers to view the site is a challenge. Especially now with the Corona Virus measures affecting us all, as many clients have been severely affected and are naturally reducing their spend on advertisements. Given this lack of revenue stream we are calling on the generosity of our readers to help us fill that void and enable our journalists to continue delivering the news that you enjoy.

Unlike many other news sites, we don't have annoying pop ups or charge scandalous prices for events. We also produce magazines for each title and make these freely available to read online, for your enjoyment. Often, people have asked why we don't make a charge for viewers to read these magazines and news stories but we feel that would adversely affect our readership/advertisers response rate. But with advertising revenues now severely affected we need your help. So, if you can support our news sites/magazines with a small donation of even £1 your generosity will help us weather the current storm and continue in our quest to deliver quality journalism.

We value your readership and your support, as this enables us to continue to provide our regular daily news updates. We've been established over 30 years, during which we've lost count of the numerous recessions and financial meltdowns, and we intend to weather the storms caused by Covid-19. So, every reader contribution, however big or small, is invaluable in helping us to get through this. Please click here to help support your favourite news site/magazine.

- Advertisement -

First generic remdesivir for COVID-19 treatment launched

Beximco Pharmaceuticals, the Bangladesh-based manufacturer of generic pharma products and APIs, has launched the world’s first generic remdesivir for treating COVID-19. Remdesivir is an antiviral...

Vividion Therapeutics partners with Roche on novel E3 ligases

San Diego biotech, Vividion Therapeutics, is collaborating with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3...

Inovio publishes positive data on COVID-19 DNA vaccine

Inovio has published preclinical study data for IN0-4800 –  its COVID-19 DNA vaccine – demonstrating robust neutralising antibody and T cell immune responses against...

mRNA-based vaccine tech emerging as frontrunner against COVID-19

Messenger RNA (mRNA) based vaccine technology is emerging as one of the frontrunners among the technologies being evaluated to develop a vaccine for COVID-19,...

Tecentriq gains first-line approval in NSCLC

The FDA has approved Roche’s Tecentriq (atezolizumab) as a first-line monotherapy for the treatment of metastatic non-small cell lung cancer (NSCLC), marking its fourth...

Related news

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...

First generic remdesivir for COVID-19 treatment launched

Beximco Pharmaceuticals, the Bangladesh-based manufacturer of generic pharma products and APIs, has launched the world’s first generic remdesivir for treating COVID-19. Remdesivir is an antiviral...

Vividion Therapeutics partners with Roche on novel E3 ligases

San Diego biotech, Vividion Therapeutics, is collaborating with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3...

Inovio publishes positive data on COVID-19 DNA vaccine

Inovio has published preclinical study data for IN0-4800 –  its COVID-19 DNA vaccine – demonstrating robust neutralising antibody and T cell immune responses against...